HC Wainwright Forecasts Reduced Earnings for Urogen Pharma

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimate for Urogen Pharma to ($0.73), reflecting a decline from the previous estimate of ($0.69).
• Urogen Pharma reported a substantial Q2 loss with an EPS of ($1.05), missing the consensus estimate of ($0.82), while revenue was higher than expected at $24.22 million.
• Despite recent downgrades, Urogen Pharma maintains a "Buy" rating from various analysts, with a consensus target price of $31.43.

Urogen Pharma (NASDAQ:URGN - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for Urogen Pharma in a research report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.73) per share for the quarter, down from their prior forecast of ($0.69). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Urogen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma's Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($1.18) EPS.

Several other research analysts have also commented on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a research note on Tuesday, August 5th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. Piper Sandler initiated coverage on shares of Urogen Pharma in a research note on Monday. They set an "overweight" rating and a $36.00 price target on the stock. Guggenheim restated a "buy" rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $32.00.

Urogen Pharma Price Performance

Urogen Pharma stock traded down $0.12 during trading hours on Thursday, hitting $19.28. The company had a trading volume of 200,518 shares, compared to its average volume of 1,556,511. The firm has a market capitalization of $891.97 million, a P/E ratio of -5.81 and a beta of 1.12. The firm's fifty day moving average is $15.70 and its 200-day moving average is $11.72. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%.

Institutional Trading of Urogen Pharma

A number of hedge funds have recently bought and sold shares of URGN. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after acquiring an additional 2,983,368 shares during the period. RTW Investments LP lifted its holdings in shares of Urogen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after acquiring an additional 47,447 shares during the period. RA Capital Management L.P. bought a new position in shares of Urogen Pharma during the 1st quarter worth about $35,461,000. Soleus Capital Management L.P. bought a new position in shares of Urogen Pharma during the 2nd quarter worth about $29,934,000. Finally, Vestal Point Capital LP lifted its holdings in shares of Urogen Pharma by 32.1% during the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock worth $23,812,000 after acquiring an additional 522,957 shares during the period. 91.29% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the sale, the general counsel directly owned 41,492 shares of the company's stock, valued at $794,156.88. This represents a 15.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,833 shares of company stock valued at $457,467. Insiders own 4.70% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.